Key points from article :
A $2 million grant will enable clinical trial of rapamycin in 40 patients with early Alzheimer’s disease.
They receive a daily dose of oral rapamycin and undergo brain health assessments.
The grant is from Part the Cloud, the Gates Foundation and the Alzheimer’s Association.
Previous studies have shown that rapamycin improved memory function in mice with Alzheimer’s disease.
Another showed that rapamycin was safe in senior adults over eight weeks.
The strongest risk factor for Alzheimer’s disease is being older.
Dr. Seshadri- "Rapamycin is effective in animal models at increasing longevity, we believe it is a very promising agent to study in this age-related disease.”
In preclinical studies, rapamycin improved functions specifically related to dementia.
The total research investment is now $60 million.
Research by UT Health San Antonio.
